Testicular lymphoma is associated with a high incidence of extranodal recurrence

Rafael Fonseca, Thomas Matthew Habermann, Joseph P. Colgan, Brian Patrick O'Neill, William L. White, Thomas Elmer Witzig, Kathleen S. Egan, James A. Martenson, Lawrence J. Burgart, David J. Inwards

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

BACKGROUND. Testicular lymphoma is a rare extranodal presentation of non-Hodgkin lymphoma. The authors report long term follow-up information regarding a group of patients with testicular lymphoma evaluated at the Mayo Clinic and describe the outcome with special attention to patterns of recurrence. METHODS. The medical records of patients with testicular lymphoma seen at the Mayo Clinic between January 1970 and March 1993 were reviewed. Patients were included if they had evidence of testicular involvement at the time of diagnosis of lymphoma. Pathology specimens were reviewed for confirmation of diagnosis. RESULTS. Sixty-two patients with a diagnosis of testicular lymphoma were identified. Their median age was 68 years, and 60 patients underwent orchiectomy as the initial therapeutic and diagnostic procedure. Most of patients (79%) had localized or regional disease at the time of presentation. Other treatment modalities after diagnosis included radiotherapy (37%), combination chemotherapy (37%), and combination chemotherapy and radiotherapy (16%). Although 88% of patients had no residual disease after primary treatment, 80% subsequently experienced disease recurrence. There was no significant difference in the rate of recurrence, including Ann Arbor Stage I disease. Treatment did not appear to affect the recurrence rate. At a median follow-up of 2.7 years, 60% of patients had died of disease. Late recurrences were observed, and there appeared to be no plateau in the disease free survival curve. In half (51%) of the patients with disease recurrence, only extranodal locations were involved. Thirteen patients experienced recurrence in the central nervous system, 11 of whom had parenchymal lesions. In 8 of these 13 patients, the central nervous system was an isolated site of disease recurrence. CONCLUSIONS. Testicular lymphoma is a unique and aggressive extranodal non-Hodgkin lymphoma. Better treatment strategies are needed to prevent recurrences. The risk of extranodal recurrence is high, especially in the central nervous system.

Original languageEnglish (US)
Pages (from-to)154-161
Number of pages8
JournalCancer
Volume88
Issue number1
DOIs
StatePublished - Jan 1 2000

Fingerprint

Lymphoma
Recurrence
Incidence
Central Nervous System
Combination Drug Therapy
Non-Hodgkin's Lymphoma
Radiotherapy
Therapeutics
Orchiectomy
Disease-Free Survival
Medical Records
Pathology

Keywords

  • Adjuvant chemotherapy
  • Combined modality therapy
  • Lymphoma
  • Radiotherapy
  • Spinal injections
  • Testicular neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Testicular lymphoma is associated with a high incidence of extranodal recurrence. / Fonseca, Rafael; Habermann, Thomas Matthew; Colgan, Joseph P.; O'Neill, Brian Patrick; White, William L.; Witzig, Thomas Elmer; Egan, Kathleen S.; Martenson, James A.; Burgart, Lawrence J.; Inwards, David J.

In: Cancer, Vol. 88, No. 1, 01.01.2000, p. 154-161.

Research output: Contribution to journalArticle

Fonseca, Rafael ; Habermann, Thomas Matthew ; Colgan, Joseph P. ; O'Neill, Brian Patrick ; White, William L. ; Witzig, Thomas Elmer ; Egan, Kathleen S. ; Martenson, James A. ; Burgart, Lawrence J. ; Inwards, David J. / Testicular lymphoma is associated with a high incidence of extranodal recurrence. In: Cancer. 2000 ; Vol. 88, No. 1. pp. 154-161.
@article{05efd423af3148b0a842debe0a6ede81,
title = "Testicular lymphoma is associated with a high incidence of extranodal recurrence",
abstract = "BACKGROUND. Testicular lymphoma is a rare extranodal presentation of non-Hodgkin lymphoma. The authors report long term follow-up information regarding a group of patients with testicular lymphoma evaluated at the Mayo Clinic and describe the outcome with special attention to patterns of recurrence. METHODS. The medical records of patients with testicular lymphoma seen at the Mayo Clinic between January 1970 and March 1993 were reviewed. Patients were included if they had evidence of testicular involvement at the time of diagnosis of lymphoma. Pathology specimens were reviewed for confirmation of diagnosis. RESULTS. Sixty-two patients with a diagnosis of testicular lymphoma were identified. Their median age was 68 years, and 60 patients underwent orchiectomy as the initial therapeutic and diagnostic procedure. Most of patients (79{\%}) had localized or regional disease at the time of presentation. Other treatment modalities after diagnosis included radiotherapy (37{\%}), combination chemotherapy (37{\%}), and combination chemotherapy and radiotherapy (16{\%}). Although 88{\%} of patients had no residual disease after primary treatment, 80{\%} subsequently experienced disease recurrence. There was no significant difference in the rate of recurrence, including Ann Arbor Stage I disease. Treatment did not appear to affect the recurrence rate. At a median follow-up of 2.7 years, 60{\%} of patients had died of disease. Late recurrences were observed, and there appeared to be no plateau in the disease free survival curve. In half (51{\%}) of the patients with disease recurrence, only extranodal locations were involved. Thirteen patients experienced recurrence in the central nervous system, 11 of whom had parenchymal lesions. In 8 of these 13 patients, the central nervous system was an isolated site of disease recurrence. CONCLUSIONS. Testicular lymphoma is a unique and aggressive extranodal non-Hodgkin lymphoma. Better treatment strategies are needed to prevent recurrences. The risk of extranodal recurrence is high, especially in the central nervous system.",
keywords = "Adjuvant chemotherapy, Combined modality therapy, Lymphoma, Radiotherapy, Spinal injections, Testicular neoplasms",
author = "Rafael Fonseca and Habermann, {Thomas Matthew} and Colgan, {Joseph P.} and O'Neill, {Brian Patrick} and White, {William L.} and Witzig, {Thomas Elmer} and Egan, {Kathleen S.} and Martenson, {James A.} and Burgart, {Lawrence J.} and Inwards, {David J.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1002/(SICI)1097-0142(20000101)88:1<154::AID-CNCR21>3.0.CO;2-T",
language = "English (US)",
volume = "88",
pages = "154--161",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Testicular lymphoma is associated with a high incidence of extranodal recurrence

AU - Fonseca, Rafael

AU - Habermann, Thomas Matthew

AU - Colgan, Joseph P.

AU - O'Neill, Brian Patrick

AU - White, William L.

AU - Witzig, Thomas Elmer

AU - Egan, Kathleen S.

AU - Martenson, James A.

AU - Burgart, Lawrence J.

AU - Inwards, David J.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - BACKGROUND. Testicular lymphoma is a rare extranodal presentation of non-Hodgkin lymphoma. The authors report long term follow-up information regarding a group of patients with testicular lymphoma evaluated at the Mayo Clinic and describe the outcome with special attention to patterns of recurrence. METHODS. The medical records of patients with testicular lymphoma seen at the Mayo Clinic between January 1970 and March 1993 were reviewed. Patients were included if they had evidence of testicular involvement at the time of diagnosis of lymphoma. Pathology specimens were reviewed for confirmation of diagnosis. RESULTS. Sixty-two patients with a diagnosis of testicular lymphoma were identified. Their median age was 68 years, and 60 patients underwent orchiectomy as the initial therapeutic and diagnostic procedure. Most of patients (79%) had localized or regional disease at the time of presentation. Other treatment modalities after diagnosis included radiotherapy (37%), combination chemotherapy (37%), and combination chemotherapy and radiotherapy (16%). Although 88% of patients had no residual disease after primary treatment, 80% subsequently experienced disease recurrence. There was no significant difference in the rate of recurrence, including Ann Arbor Stage I disease. Treatment did not appear to affect the recurrence rate. At a median follow-up of 2.7 years, 60% of patients had died of disease. Late recurrences were observed, and there appeared to be no plateau in the disease free survival curve. In half (51%) of the patients with disease recurrence, only extranodal locations were involved. Thirteen patients experienced recurrence in the central nervous system, 11 of whom had parenchymal lesions. In 8 of these 13 patients, the central nervous system was an isolated site of disease recurrence. CONCLUSIONS. Testicular lymphoma is a unique and aggressive extranodal non-Hodgkin lymphoma. Better treatment strategies are needed to prevent recurrences. The risk of extranodal recurrence is high, especially in the central nervous system.

AB - BACKGROUND. Testicular lymphoma is a rare extranodal presentation of non-Hodgkin lymphoma. The authors report long term follow-up information regarding a group of patients with testicular lymphoma evaluated at the Mayo Clinic and describe the outcome with special attention to patterns of recurrence. METHODS. The medical records of patients with testicular lymphoma seen at the Mayo Clinic between January 1970 and March 1993 were reviewed. Patients were included if they had evidence of testicular involvement at the time of diagnosis of lymphoma. Pathology specimens were reviewed for confirmation of diagnosis. RESULTS. Sixty-two patients with a diagnosis of testicular lymphoma were identified. Their median age was 68 years, and 60 patients underwent orchiectomy as the initial therapeutic and diagnostic procedure. Most of patients (79%) had localized or regional disease at the time of presentation. Other treatment modalities after diagnosis included radiotherapy (37%), combination chemotherapy (37%), and combination chemotherapy and radiotherapy (16%). Although 88% of patients had no residual disease after primary treatment, 80% subsequently experienced disease recurrence. There was no significant difference in the rate of recurrence, including Ann Arbor Stage I disease. Treatment did not appear to affect the recurrence rate. At a median follow-up of 2.7 years, 60% of patients had died of disease. Late recurrences were observed, and there appeared to be no plateau in the disease free survival curve. In half (51%) of the patients with disease recurrence, only extranodal locations were involved. Thirteen patients experienced recurrence in the central nervous system, 11 of whom had parenchymal lesions. In 8 of these 13 patients, the central nervous system was an isolated site of disease recurrence. CONCLUSIONS. Testicular lymphoma is a unique and aggressive extranodal non-Hodgkin lymphoma. Better treatment strategies are needed to prevent recurrences. The risk of extranodal recurrence is high, especially in the central nervous system.

KW - Adjuvant chemotherapy

KW - Combined modality therapy

KW - Lymphoma

KW - Radiotherapy

KW - Spinal injections

KW - Testicular neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0033985440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033985440&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(20000101)88:1<154::AID-CNCR21>3.0.CO;2-T

DO - 10.1002/(SICI)1097-0142(20000101)88:1<154::AID-CNCR21>3.0.CO;2-T

M3 - Article

VL - 88

SP - 154

EP - 161

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -